Business Context and Reporting Period
Company: Corcept Therapeutics Incorporated (CORT)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Corcept is a commercial-stage biopharmaceutical company focused on modulating cortisol to treat endocrinologic, oncologic, metabolic, and neurologic disorders. Its primary commercial product is Korlym (mifepristone) for hypercortisolism (Cushing's syndrome), alongside an authorized generic version. The company maintains a robust pipeline of proprietary selective cortisol modulators, including relacorilant (oncology and hypercortisolism), nenocorilant (oncology), miricorilant (MASH), and dazucorilant (ALS).
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net Product Revenue | $761.4 | $675.0 | $482.4 |
| Cost of Sales | $13.0 | $10.9 | $6.5 |
| Gross Margin | 98.3% | 98.4% | 98.7% |
| Research & Development Expense | $254.9 | $246.9 | $184.4 |
| Selling, General & Admin Expense | $448.7 | $280.3 | $184.3 |
| Income from Operations | $44.8 | $137.0 | $107.3 |
| Net Income | $99.7 | $141.2 | $106.1 |
| Diluted EPS | $0.82 | $1.23 | $0.94 |
| Cash, Equivalents & Marketable Securities | $532.4 | $603.2 | N/A |
| Net Cash Provided by Operating Activities | $142.0 | $198.3 | $126.7 |
Note: The filing text does not provide a specific long-term debt balance; the company relies on cash reserves and operating cash flow to fund operations.
Material Changes vs. Prior Period
- Revenue Growth: Net product revenue increased 12.8% year-over-year to $761.4 million, driven by a 37.0% increase in sales volume. This was partially offset by a 17.7% decrease in average selling price due to higher volume sales of the authorized generic version of Korlym.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses surged 60% to $448.7 million, primarily due to increased sales and marketing activities to support commercialization. R&D expenses increased 3.2% to $254.9 million.
- Profitability: Despite revenue growth, Net Income declined 29.4% to $99.7 million, and Income from Operations dropped 67.3% to $44.8 million, largely due to the significant increase in SG&A expenses.
- Pharmacy Vendor Transition: The company transitioned specialty pharmacy services from Optime Care, Inc. to Curant Health Georgia, LLC in Q4 2025. The filing notes that revenue would have been materially higher in 2025 had the previous vendor been able to fully meet demand.
- Stock Repurchases: The company spent $172.9 million repurchasing common stock under its Stock Repurchase Program in 2025, compared to $15.7 million in 2024.
Guidance, Outlook, Risks, and Unusual Items
Regulatory Developments
- Relacorilant (Hypercortisolism): On December 30, 2025, the FDA issued a Complete Response Letter (CRL) declining approval for relacorilant for hypercortisolism, stating additional evidence of efficacy is required. The company is working with the FDA to determine the path forward.
- Relacorilant (Oncology): The FDA accepted the NDA for relacorilant in combination with nab-paclitaxel for platinum-resistant ovarian cancer in September 2025, with a PDUFA date of July 11, 2026. The company announced in January 2026 that the pivotal ROSELLA trial met its Overall Survival (OS) primary endpoint.
- Dazucorilant (ALS): While the Phase 2 DAZALS trial did not meet its primary endpoint, an exploratory analysis showed an 84% reduction in the risk of death for patients on the 300 mg dose. A pivotal Phase 3 trial is expected to start in 2026.
Risks and Contingencies
- Patent Litigation: On February 19, 2026, the Federal Circuit affirmed a District Court ruling that Teva's generic version of Korlym does not infringe Corcept's patents. This confirms the presence of generic competition.
- Antitrust Litigation: Teva filed an antitrust lawsuit against Corcept and its former pharmacy vendor, Optime. The case is scheduled for trial in March 2027.
- Securities Class Action: A purported securities class action was filed on February 20, 2026, alleging misleading statements regarding the relacorilant NDA for hypercortisolism.
- Government Investigation: The company is cooperating with a records subpoena from the U.S. Attorney's Office for the District of New Jersey regarding the sale and promotion of Korlym.
- Regulatory Environment: The Inflation Reduction Act (IRA) and the "One Big Beautiful Bill Act" (OBBBA) of 2025 introduce price negotiation mechanisms and Medicaid funding reductions that may impact future revenue.
Investor Verification Checklist
- Relacorilant Approval Path: Verify the specific additional data or trials the FDA requires for relacorilant approval in hypercortisolism following the December 2025 CRL.
- Pharmacy Transition Impact: Assess the full financial impact of the transition from Optime to Curant on Q4 2025 and Q1 2026 revenue, given the stated demand constraints.
- Generic Competition: Monitor the market share erosion of Korlym due to Teva's generic entry and the confirmed non-infringement of Corcept's patents.
- SG&A Efficiency: Evaluate the return on investment for the 60% increase in SG&A spending and whether this level of expense is sustainable relative to revenue growth.
- Legal Exposure: Review the status of the Teva antitrust litigation and the New Jersey government investigation for potential financial liabilities.